Coronary Artery Disease Clinical Trial Space Intensifies With 20+ Companies In Active Development Delveinsight

Arunima Dabral, Assistant Project Manager of Consulting and Competitive Intelligence, said that the CAD treatment landscape is evolving with increasing focus on addressing residual cardiovascular risk beyond conventional lipid-lowering and antithrombotic therapies. Emerging approaches targeting Lp(a), inflammation, plaque progression, and thrombosis are expected to expand treatment options for high-risk patients. The growing development of long-acting and genetically targeted therapies may further transform CAD management by enabling more durable risk reduction.

Recent Developments in Coronary Artery Disease Treatment Space

• In July 2026, Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced positive results from a Phase IIa study evaluating vortosiran (RBD4059), an siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD). The randomized, double-blind, placebo-controlled study demonstrated that vortosiran was generally well tolerated and achieved profound, dose-dependent, and sustained suppression of FXI activity in patients receiving standard-of-care aspirin treatment.
• In May 2026, Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the submission of a Phase II clinical trial application to the European Medicines Agency for RBD1119, an siRNA-based therapeutic being developed for the treatment of coronary artery disease. The submission marked an advancement of Ribo's oligonucleotide-based therapeutic pipeline targeting thromboembolic and cardiovascular diseases.
• n March 2026, Sirius Therapeutics announced that the first patient had been dosed in a Phase II clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI)-targeting siRNA, in patients with chronic coronary and/or peripheral arterial disease. SRSD107 is being co-developed by Sirius Therapeutics and CRISPR Therapeutics as a potential treatment for cardiovascular and clotting-related diseases.
• In January 2025, XyloCor Therapeutics announced a USD 67.5 million Series B financing to advance the clinical development of XC001 (encoberminogene rezmadenovec), an investigational gene therapy for refractory angina associated with advanced coronary artery disease. The financing was intended to support a randomized, double-blind Phase IIb EXACT-2 trial evaluating XC001 through endocardial administration, as well as a separate Phase II trial evaluating XC001 as an adjunctive treatment to coronary artery bypass graft surgery.
• In August 2025, Abcentra LLC announced that the first patient had been dosed in the Phase IIb FORTIFY trial evaluating orticumab in patients with a history of type 1 myocardial infarction and elevated coronary inflammation. Orticumab is an investigational monoclonal antibody targeting oxidized LDL, and the company is developing it for secondary prevention of cardiac events following acute coronary syndrome.

Scope of the Coronary Artery Disease Pipeline Report

• Coverage: Global
• Coronary Artery Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Coronary Artery Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Coronary Artery Disease Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Coronary Artery Disease Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Coronary Artery Disease Therapeutics Assessment By Mechanism of Action: CD44 antigen inhibitors, HMG-CoA reductase inhibitors, Gene transference, Vascular endothelial growth factor replacements, Factor XI expression inhibitors, Immunomodulators, LDL receptor antagonists, RNA interference, Cell replacements, and others
• Key Coronary Artery Disease Companies: Beijing Inno Medicine Co., Ltd., Hexun Biosciences, XyloCor Therapeutics, Inc., Sirius Therapeutics, Abcentra, Roche, Verve Therapeutics, Inc., Suzhou Ribo Life Science, Amgen, Idorsia Pharmaceuticals, and others.
• Key Coronary Artery Disease Pipeline Therapies: YN001, HeXell-2020, XC001, SRSD107, Orticumab, RO7763505, VERVE-102, RBD1119, RBD4059, Evolocumab, Selatogrel, and others.

Coronary Artery Disease News

Table of Contents

1.	Coronary Artery Disease Pipeline Report Introduction
2.	Coronary Artery Disease Pipeline Report Executive Summary
3.	Coronary Artery Disease Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Coronary Artery Disease Clinical Trial Therapeutics
6.	Coronary Artery Disease Pipeline: Late-Stage Products (Pre-registration)
7.	Coronary Artery Disease Pipeline: Late-Stage Products (Phase III)
8.	Coronary Artery Disease Pipeline: Mid-Stage Products (Phase II)
9.	Coronary Artery Disease Pipeline: Early-Stage Products (Phase I)
10.	Coronary Artery Disease Pipeline Therapeutics Assessment
11.	Inactive Products in the Coronary Artery Disease Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Coronary Artery Disease Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the Coronary Artery Disease clinical trials, reach out @ Coronary Artery Disease Medication

Related Reports

Coronary Artery Disease Market

Coronary Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Coronary Artery Disease companies, including Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, AskBio, and others.

Coronary Artery Disease Treatment Devices Market

Coronary Artery Disease Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key CHF treatment devices companies, including GE HealthCare, Boston Scientific Corporation, Medtronic, Abbott, Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others.

Chronic Heart Failure Market

Chronic Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key chronic heart failure companies, including Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others.

Acute Heart Failure Market

Acute Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute heart failure companies, including Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others.

Advanced Heart Failure Market

Advanced Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .

CONTACT: Contact Us Shruti Thakur... +14699457679